Flecainide inhalation - InCarda Therapeutics

Drug Profile

Flecainide inhalation - InCarda Therapeutics

Alternative Names: Inhaled flecainide - InCarda Therapeutics; InRhythm™

Latest Information Update: 21 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InCarda Therapeutics
  • Class Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Paroxysmal atrial fibrillation

Most Recent Events

  • 09 Aug 2017 InCarda Therapeutics completes a phase I trial in Paroxysmal atrial fibrillation (In volunteers) in Australia (ACTRN12616001156471)
  • 07 Jun 2017 Pharmacokinetics data from a phase I trial in Paroxysmal atrial fibrillation released by InCarda Therapeutics
  • 07 Jun 2017 InCarda Therapeutics plans a clinical trial for Paroxysmal atrial fibrillation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top